Asparaginase pharmacokinetics and implications of therapeutic drug monitoring

Abstract

Asparaginase is widely used in chemotherapeutic regimens for the treatment of acute lymphoblastic leukemia (ALL) and has led to a substantial improvement in cure rates, especially in children. Optimal therapeutic effects depend on a complete and sustained depletion of serum asparagine. However, pronounced interpatient variability, differences in pharmacokinetic properties between asparaginases and the formation of asparaginase antibodies make it difficult to predict the degree of asparagine depletion that will result from a given dose of asparaginase. The pharmacological principles underlying asparaginase therapy in the treatment of ALL are summarized in this article. A better understanding of the many factors that influence asparaginase activity and subsequent asparagine depletion may allow physicians to tailor treatment to the individual, maximizing therapeutic effect and minimizing treatment-related toxicity. Therapeutic drug monitoring provides a means of assessing a patient's current depletion status and can be used to better evaluate the potential benefit of treatment adjustments.

Keywords::

• Asparaginase
• acute lymphoblastic leukemia
• pharmacokinetics
• hypersensitivity
• silent inactivation
• therapeutic drug monitoring

Acknowledgements

Dr. Rizzari gratefully acknowledges the support received for his scientific activities from the Comitato M. L. Verga for the study and treatment of childhood leukemia. Editorial assistance was provided by Cory Hussar, PhD, of The Curry Rockefeller Group, LLC, Tarrytown, NY, USA, and supported by Jazz Pharmaceuticals plc or its subsidiaries.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.